2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.101 (Poster) Estimated Cost of Adverse Events and Surgery for Patients With Resectable Non small Cell Lung Cancer Who Are Receiving Neoadjuvant Nivolumab Plus Platinum Doublet Chemotherapy

PP01.101 (Poster) Estimated Cost of Adverse Events and Surgery for Patients With Resectable Non small Cell Lung Cancer Who Are Receiving Neoadjuvant Nivolumab Plus Platinum Doublet Chemotherapy

Back to course

Pdf Summary

A study was conducted to estimate the cost of adverse events (AEs), surgery, and medical resource use (MRU) in patients receiving neoadjuvant nivolumab plus platinum-doublet chemotherapy (NPDC) compared to platinum-doublet chemotherapy (PDC) for resectable non-small cell lung cancer (rNSCLC) from a US commercial payer perspective. The study found that the estimated cost of AEs, surgery, and MRU in the first year of treatment was 5.7% lower per patient receiving NPDC compared to PDC. This was primarily driven by lower costs associated with neoadjuvant AEs, adjuvant AEs, and surgical complications. Patients receiving NPDC were estimated to have fewer adjuvant AE costs due to reduced use of adjuvant therapy. The estimated average cost of surgery per patient receiving NPDC was slightly higher than PDC, but for patients undergoing definitive surgery, the estimated average cost was slightly lower for NPDC compared to PDC. The study did not capture the impact of treatment cost and downstream medical resource use for disease management after progression. However, it is anticipated that further cost reductions will be realized in the future due to delayed progression events in the NPDC arm. Overall, the study concluded that patients receiving NPDC incurred lower total costs in the first year of treatment compared to patients receiving PDC.

Asset Subtitle

Paul Lozowicki

Keywords

adverse events

surgery

medical resource use

neoadjuvant nivolumab

platinum-doublet chemotherapy

resectable non-small cell lung cancer

US commercial payer perspective

cost estimation

adjuvant therapy

definitive surgery